Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 297 full-time employees. The company went IPO on 2020-07-02. The firm is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The firm develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
Follow-Up Questions
What is Immatics NV (IMTX)'s P/E Ratio?
The P/E ratio of Immatics NV is 70.7889
Who is the CEO of Immatics NV?
Dr. Harpreet Singh is the Chief Executive Officer of Immatics NV, joining the firm since 2020.
What is the price performance of IMTX stock?
The current price of IMTX is $9.68, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Immatics NV?
Immatics NV belongs to Biotechnology industry and the sector is Health Care
What is Immatics NV market cap?
Immatics NV's current market cap is $1.1B
Is Immatics NV a buy, sell, or hold?
According to wall street analysts, 12 analysts have made analyst ratings for Immatics NV, including 6 strong buy, 7 buy, 1 hold, 0 sell, and 6 strong sell
